The minimum number of target lesions that need to be measured to be representative of the total number of target lesions (according to RECIST)
- 1 August 2009
- journal article
- Published by Oxford University Press (OUP) in The British Journal of Radiology
- Vol. 82 (980), 681-686
- https://doi.org/10.1259/bjr/72829563
Abstract
Response evaluation criteria in solid tumours (RECIST) were introduced as a means to classify tumour response with no definition of the minimum number of lesions. This study was conducted in order to evaluate discrepancies between full assessments based on either all target lesions or fewer lesions. RECIST evaluation was performed on separate occasions based on between one and seven of the target lesions, with simultaneous assessment of non-target lesions. 99 patients were included. 38 patients demonstrated progressive disease, in 61% of whom it was a result of the appearance of new lesions or unequivocal progress in non-target lesions. 32 patients showed stable disease, with 8 having results that differed when 1–3 target lesions were measured. 22 cases were considered as having partial regression, with only 1 case differing when performing 1–3 target lesion assessments. Seven cases demonstrated complete response. The number of discordant cases increased gradually from measuring three lesions to one target lesion. The average number of available target lesions among those with discrepancies was 7.1, which was significantly higher than those demonstrating concordance (4.1 lesions; p<0.05). In conclusion, measuring fewer than four target lesions might cause discrepancies when more than five target lesions are present.Keywords
This publication has 17 references indexed in Scilit:
- Radiologic Measurements of Tumor Response to Treatment: Practical Approaches and LimitationsRadioGraphics, 2008
- Response evaluation: beyond RECISTAnnals of Oncology, 2007
- Development of adapted RECIST criteria to assess response in lymphoma and their comparison to the International Workshop CriteriaLeukemia & Lymphoma, 2007
- Sometimes Size Doesn't Matter: Reevaluating RECIST and Tumor Response Rate EndpointsJNCI Journal of the National Cancer Institute, 2006
- Measures of Response: RECIST, WHO, and New AlternativesJournal of Clinical Oncology, 2006
- RECIST revisited: A review of validation studies on tumour assessmentEuropean Journal of Cancer, 2006
- Comparison of linear and volumetric criteria in assessing tumor response in adult high-grade gliomas1Neuro-Oncology, 2006
- Prostate Cancer Clinical Trial End Points: “RECIST”ing a Step BackwardsClinical Cancer Research, 2005
- Limitations with the response evaluation criteria in solid tumors (RECIST) guidance in disseminated pediatric malignancyPediatric Blood & Cancer, 2005
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000